A user-friendly approach to drug delivery device development

Cutting-edge design that puts the patient first is at the heart of a new drug delivery device for multiple sclerosis (MS) sufferers. Product design and development firm Cambridge Consultants has worked with leading pharmaceutical company Novartis and medical device manufacturer Owen Mumford – plus hundreds of MS patients – to come up with the ExtaviPro® 30G auto-injector.

From its attractive visual design and ergonomic shape to its easy-to-read adjustable needle depth control, the ExtaviPro 30G has been designed with the needs of the patient in mind. More than 500 MS patients and healthcare professionals in the US, the UK and mainland Europe were involved in the development process to ensure the device was underpinned by a deep understanding of the users.

An estimated 2.5 million people worldwide have MS – a disease affecting the central nervous system. Symptoms can include vision problems, tingling and tremors, dizziness, balance problems, restricted mobility, fatigue and cognitive issues. The ExtaviPro 30G is aimed at people who suffer from relapsing forms of MS – such as clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) – who make up the majority of MS patients. They have periods when symptoms flare up aggressively, known as relapses, followed by periods of recovery – or remission. They often have to self-inject prescription medication at home to help reduce the impact and frequency of relapses.

“Our aim was to make the ExtaviPro 30G auto-injector very simple and intuitive to use, and enable one-handed injection,” said Andy Pidgeon, head of the industrial design and human factors group at Cambridge Consultants. “Its ergonomic shape leads patients to instinctively hold it correctly – which is vital for those who suffer from tremors, as having a firm grip is key to self-injecting safely.

“Another key factor was the feedback we received during our extensive user research. Patients wanted a soft, non-threatening design, for example – so we’ve made it very user friendly. And it’s led to the creation of a drug delivery device that doesn’t look like a badge of infirmity.”

As well as the look and feel of the auto-injector, Cambridge Consultants also developed the accompanying instruction leaflets – ensuring they were clear for MS sufferers with cognitive problems – as well as the travel bag for carrying the device and supplies for injections. To ensure the design truly reflected the needs and desires of patients, even the bag went through several rounds of user studies to ensure it best suited individual lifestyles.

The ExtaviPro 30G auto-injector has been launched in Europe – initially in Germany.

Notes to editors

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 900 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical and life science, industrial and energy, consumer and retail, and communications and infrastructure. For more information, visit: www.cambridgeconsultants.com

Cambridge Consultants is part of Capgemini Invent, the innovation, consulting and transformation brand of the Capgemini Group. Capgemini Invent helps CxOs envision and build what’s next for their organisations. Located in more than 30 offices and 25 creative studios around the world, its 7,000+ strong team combines strategy, technology, data science and creative design with deep industry expertise and insights, to develop new digital solutions and business models of the future.

Capgemini Invent is an integral part of Capgemini, a global leader in partnering with companies to transform and manage their business by harnessing the power of technology. The Group is guided everyday by its purpose of unleashing human energy through technology for an inclusive and sustainable future. It is a responsible and diverse organisation of 270,000 team members in nearly 50 countries. With its strong 50 year heritage and deep industry expertise, Capgemini is trusted by its clients to address the entire breadth of their business needs, from strategy and design to operations, fueled by the fast evolving and innovative world of cloud, data, AI, connectivity, software, digital engineering and platforms. The Group reported in 2020 global revenues of €16 billion.

Get the Future You Want | www.capgemini.com

Media downloads

pr-pr14-007_image1ex_v0.9.jpg, 7.3MB
pr-pr14-007_image2_v0.9.jpg, 0.7MB
pr-pr14-007_image3ex_v0.9.jpg, 5.6MB
pr-pr14-007_image4ex_v0.9.jpg, 6MB

PRESS CONTACTS

Ketchum UK

Josh
Salisbury
Account Director